Skip to content
UpArrowheadUpArrowheadUpArrowheadK5K5K5

Drawing based on the label description. No photo yet.

UpArrowhead K5 pill

Pill with imprint UpArrowhead K5 is white, round, 9 mm and has been identified as Clomiphene Citrate 50 mg. It is used for female infertility and male infertility. It is supplied by Advagen Pharma Ltd.

Clomiphene Citrate 50 mg

Imprint
UpArrowhead K5
Strength
50 mg
Used for
Female infertility and male infertility
Color
White
Shape
Round
Size
9 mm
Score
Breaks into 2 pieces
Form
Tablet
Manufacturer
Advagen Pharma Ltd
Drug class
Estrogen modulator
NDC
72888-213, 72888-213-08, 72888-213-58

Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .

Report a mistake

Please do not include personal health information. For questions about your medicine, ask a pharmacist.

All Clomiphene Citrate pills and guides

What is Clomiphene Citrate used for?

Clomiphene Citrate is used for female infertility and male infertility.

Medicine type
Estrogen modulator
Official uses from the US prescribing label

Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS: Ovarian Hyperstimulation Syndrome), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology.

Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS.)

Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below:

  1. Patients who are not pregnant.
  2. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment.
  3. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present.
  4. Patients with normal liver function.

In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following:

  1. Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy.
  2. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure.
  3. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population.
  4. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility.
  5. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids.

There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known.

Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (ie, clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses.

From the FDA-approved label on DailyMed (published Sep 02, 2026).

Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.

Is this your pill? Check every detail

  • Your pill shows UpArrowhead K5. The parts can be split between the two sides, so turn the pill over and check both.
  • It is white, round, 9 mm.
  • Its score line and coating match the details on this page.
  • It came from a pharmacy package that names the same drug.

Ingredients

Active: Clomiphene Citrate

Inactive: Starch, Corn, Lactose Monohydrate, Magnesium Stearate, Sucrose

Pills that look similar but are different drugs

Same color and shape, different medicine. This is why the imprint matters.

Other Clomiphene Citrate pills